Adaptimmune Therapeutics PLC (NAS:ADAP)
$ 0.6984 -0.0248 (-3.43%) Market Cap: 178.71 Mil Enterprise Value: 73.46 Mil PE Ratio: 0 PB Ratio: 2.25 GF Score: 64/100

Adaptimmune Therapeutics PLC at Citi Immuno-Oncology Summit (Virtual) Transcript

Feb 17, 2022 / 03:00PM GMT
Release Date Price: $3 (-3.23%)
Yigal Dov Nochomovitz
Citigroup Inc., Research Division - Director

Welcome, everyone, to day 2 of Citi's Immuno-Oncology Summit. I am Yigal Nochomovitz, one of the biotech analysts here at Citi. Most of you know me. (Operator Instructions)

So with that, it's my great pleasure to welcome the management team from Adaptimmune. We have Gavin Wood, CFO; Elliot Norry, CMO; and Juli Miller, VP IR. So welcome, everyone. Thank you so much for taking the time. Maybe just to start out, Gavin, if you would like to summarize the overall strategy for Adaptimmune for those listeners that are less familiar with the story?

Adrian G. Rawcliffe
Adaptimmune Therapeutics plc - CEO, Principal Accounting Officer & Director

It's Ad Rawcliffe, CEO. I'll just touch on areas of focus for this year. Adaptimmune is a late-stage, integrated cell therapy company, focused on the TCR T-cell space for solid tumors. We have a strategy that we laid out a couple of years ago. It's unashamedly a product-oriented strategy as we're leading in late-stage clinical trials and approaching

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot